Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Raynaud's phenomenon induced by sulphasalazine.

Literature DB >> 6104805

Raynaud's phenomenon induced by sulphasalazine.

Abstract

Sulphasalazine-induced Raynaud's phenomenon is reported in a patient who showed no other features of a drug-induced lupus syndrome. The vascular disturbance disappeared when the drug was withdrawn on 3 occasions. A simple technique for assessing the circulatory abnormality in Raynaud's phenomenon is described.

Entities: Chemical Disease Species

Mesh：

Substances：
Sulfasalazine

Year: 1980 PMID： 6104805 PMCID： PMC2425510 DOI： 10.1136/pgmj.56.652.106

Source DB: PubMed Journal: Postgrad Med J ISSN： 0032-5473 Impact factor: 2.401

4 in total

1. LUPUS ERYTHEMATOSUS CELL PHENOMENON IN PATIENTS WITH CHRONIC ULCERATIVE COLITIS.

Authors: D ALARCON SEGOVIA; T HERSKOVIC; W H DEARING; L G BARTHOLOMEW; J C CAIN; R G SHORTER
Journal: Gut Date: 1965-02 Impact factor: 23.059

2. Sulphasalazine-induced lupus syndrome in ulcerative colitis.

Authors: I D Griffiths; S P Kane
Journal: Br Med J Date: 1977-11-05

Review 3. Drug-induced lupus syndromes.

Authors: D Alarcón-Segovia
Journal: Mayo Clin Proc Date: 1969-09 Impact factor: 7.616

4. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors: K M Das; M A Eastwood; J P McManus; W Sircus
Journal: N Engl J Med Date: 1973-09-06 Impact factor: 91.245

4 in total

7 in total

Raynaud's phenomenon induced by sulphasalazine.

1. LUPUS ERYTHEMATOSUS CELL PHENOMENON IN PATIENTS WITH CHRONIC ULCERATIVE COLITIS.

2. Sulphasalazine-induced lupus syndrome in ulcerative colitis.

Review 3. Drug-induced lupus syndromes.

4. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Review 1. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Review 2. Sulfasalazine. Adverse effects and desensitization.

Review 3. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Review 4. Juvenile rheumatoid arthritis: therapeutic perspectives.

Review 5. Comparative tolerability of treatments for inflammatory bowel disease.

6. Secukinumab-induced Raynaud's phenomenon: first report in the literature.

Review 7. Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.